Cardinal Health (CAH) Stock: Hits Fresh Momentum After Strong Q2 and $750M Buyback Boost

TLDR

• Cardinal Health stock surges 9% after earnings beat and outlook raise
• Revenue climbs 19% as specialty segment drives profit expansion
• $750M buyback reduces shares and boosts EPS momentum
• Segment profits jump sharply on scale and cost discipline
• FY26 guidance lifted with double-digit earnings growth ahead

Cardinal Health (CAH) shares advanced sharply as the stock traded at $225.88, up 9.20%, reflecting strong momentum after a solid earnings release. The company reported broad gains across revenue, earnings, and segment performance, and it strengthened its outlook for fiscal 2026. The market reacted to the stronger guidance and the completed $750 million buyback, and the move marked renewed confidence in operational execution.

Cardinal Health, Inc., CAH

Stronger Q2 Results Drive Upward Shift

Cardinal Health posted revenue of $65.6 billion for the second quarter, and the figure increased 19% from last year. The company reported GAAP operating earnings of $707 million, and the result rose 29%. Non-GAAP operating earnings reached $877 million, and the figure reflected a 38% expansion alongside a lower share count.

The company reported GAAP diluted EPS of $1.97, and non-GAAP diluted EPS reached $2.63. The growth came from higher operating earnings, and financing costs from recent acquisitions partly offset this strength. Net earnings attributable to the company reached $467 million, and non-GAAP net earnings stood at $624 million.

Cardinal Health completed its annual baseline repurchase of $750 million, and this reduced the diluted share count. The company also reached its targeted leverage range, and this supported its enhanced capital deployment strategy. The second quarter results reinforced ongoing operating discipline, and momentum continued across all reporting segments.

Segment Gains Reinforce Execution Strength

The Pharmaceutical and Specialty Solutions segment delivered revenue of $60.7 billion, and this reflected a 19% gain from expanding customer activity. Segment profit rose 29% to $687 million, and contributions from specialty products and MSO acquisitions strengthened results. The generics program provided additional support, and performance aligned with rising brand product demand.

The Global Medical Products and Distribution segment generated $3.3 billion in revenue, and this represented a 3% increase from higher customer volumes. Segment profit improved 106% to $37 million, and cost optimization programs supported this expansion. Tariff impacts partially offset these gains, and the segment maintained solid operational efficiency.

Other revenue reached $1.7 billion, and the figure advanced 34% due to growth across at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics. Segment profit rose 52% to $179 million, and scale benefits supported the expansion. The acquisition of Advanced Diabetes Supply boosted the portfolio, and demand strengthened across multiple channels.

FY26 Outlook Raised as Strategic Plans Advance

Cardinal Health lifted its fiscal 2026 non-GAAP EPS guidance to $10.15 to $10.35, and the revision indicated 23% to 26% growth. The Pharmaceutical and Specialty Solutions segment profit outlook rose to 20% to 22%, and this reflected sustained strength in specialty markets. The Global Medical Products and Distribution segment profit target increased to about $150 million, and the Other segment profit growth outlook rose to 33% to 35%.

The company also lowered its non-GAAP effective tax rate outlook to 21% to 23%, and the expectation supported its profitability targets. Diluted weighted average shares decreased to a range of 237 million to 238 million, and the reduction followed continued buybacks. Management highlighted new MSO acquisitions, expanded at-Home offerings, and cultural certifications as key achievements.

Cardinal Health completed an additional $375 million accelerated repurchase program in the quarter, and this brought year-to-date repurchases to $750 million. The Specialty Alliance completed the acquisition of Solaris Health, and this strengthened its multi-specialty MSO footprint. The company also advanced diabetes support programs and formed new retail partnerships, and these efforts expanded its patient access strategy.

The post Cardinal Health (CAH) Stock: Hits Fresh Momentum After Strong Q2 and $750M Buyback Boost appeared first on CoinCentral.